Infliximab for Paradoxical Reactions in Pediatric Central Nervous System Tuberculosis | Zendy

YaraNatalie Abo | Zendy; Nigel Curtis | Zendy; Joshua Osowicki | Zendy; Gabrielle M. Haeusler | Zendy; Rachael Purcell | Zendy; Seilesh Kadambari | Zendy; Matthias De Wachter | Zendy; Koen Vanden Driessche | Zendy; Sven Dekeyzer | Zendy; Lee Coleman | Zendy; Nigel W. Crawford | Zendy; Stephen M. Graham | Zendy; Ben J. Marais | Zendy; Amanda Gwee | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Infliximab for Paradoxical Reactions in Pediatric Central Nervous System Tuberculosis

Author(s) -

YaraNatalie Abo,

Nigel Curtis,

Joshua Osowicki,

Gabrielle M. Haeusler,

Rachael Purcell,

Seilesh Kadambari,

Matthias De Wachter,

Koen Vanden Driessche,

Sven Dekeyzer,

Lee Coleman,

Nigel W. Crawford,

Stephen M. Graham,

Ben J. Marais,

Amanda Gwee

Publication year - 2021

Publication title -

journal of the pediatric infectious diseases society

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.269

H-Index - 31

eISSN - 2048-7207

pISSN - 2048-7193

DOI - 10.1093/jpids/piab094

Subject(s) - medicine , infliximab , paradoxical reaction , central nervous system , tuberculosis , complication , human immunodeficiency virus (hiv) , pediatrics , intensive care medicine , immunology , surgery , pathology , tumor necrosis factor alpha

Paradoxical reactions in central nervous system tuberculosis (CNS-TB) are associated with significant morbidity and mortality. We describe 4 HIV-uninfected children treated for CNS-TB with severe paradoxical reactions unresponsive to corticosteroids. All made recovery after treatment with infliximab, highlighting the safety and effectiveness of infliximab for this complication, and need for prospective trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research